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Abstract: Mexiletine is a commonly used Class IB (Vaughan William classification) 
antiarrhythmic drug. We report a case of mexiletine-induced psychosis that was successfully 
managed by decreasing the dose and using alternative medications for management of ven-
tricular tachycardia.
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Introduction
Mexiletine is an oral congener of lidocaine, which is commonly used as a second-line 
agent for treatment of ventricular tachycardia. Although neurological side effects have 
been reported, to the best of our knowledge, this is the first case of mexiletine-induced 
psychosis reported in the English literature.
Case report
The patient was a 19-year-old man with a past medical history significant for surgi-
cally repaired ventricular septal defect, resected subaortic stenosis, a mechanical 
aortic valve, and a dual chamber internal cardiac defibrillator. About 1 year prior to 
his index hospitalization, amiodarone was stopped because of thyrotoxicosis and the 
patient was started on metoprolol 100 mg and mexiletine 150 mg, both taken twice 
a day. The mexiletine dose was increased to 300 mg twice a day because the patient 
continued to have runs of nonsustained ventricular tachycardia leading to antitachy-
cardia pacing therapies. He presented to the inpatient psychiatry service 3 weeks after 
the dose increase, with a 2-week history of progressively increasing flat affect and 
delusional thoughts. Based on the clinical presentation, a diagnosis of acute psychosis 
was considered. There was no prior history of any psychiatric illness. There was no 
history of fever, and laboratory work did not show any leukocytosis. His serum elec-
trolytes, renal and hepatic function, serum thyroid-stimulating hormone, and blood 
vitamin B12 levels were within the normal range. Computed tomography of the head 
did not show evidence of any acute intracranial process, and a urine drug screen was 
negative. Mexiletine was discontinued given the temporal correlation between his 
symptoms and the recent increase in mexiletine dose, and he was started on sotalol 
120 mg twice a day. Risperidone and haloperidol were used on an as-needed basis for 
control of psychotic symptoms.
On the next day, the patient’s sensorium worsened and he developed catatonia. 
Antipsychotic medications were stopped and the dosage of sotalol was reduced to 
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80 mg twice a day. The patient’s sensorium improved after 
stopping the antipsychotics and decreasing the dose of sotalol. 
During the course of his 12-day hospital stay, his psychotic 
symptoms resolved. The patient was continued on sotalol 
80 mg twice a day for control of ventricular tachycardia. 
He was seen in the electrophysiology clinic at a 3-month 
follow-up visit. The patient did not have any recurrence of 
psychotic symptoms and his intracardiac device interrogation 
did not show any runs of sustained or nonsustained ventricu-
lar tachycardia. The patient is being followed up closely in 
our electrophysiology clinic.
Discussion
Mexiletine is a Class IB oral antiarrhythmic medication 
with a mechanism of action similar to that of lidocaine, and 
it is used for management of ventricular tachycardia.1 It is 
generally used in 100–300 mg doses three times a day, with a 
maximum recommended dose of 1200 mg/day. Neurological 
side effects are common, but are usually limited to headache, 
insomnia, tremors, dizziness, and fatigue, and seizures have 
been occasionally reported.1 Most of these side effects are 
dose-related and resolve with dose adjustment. Psychosis has 
been reported previously with quinidine2 and procainamide3 
(Class IA agents), lidocaine4 (a Class IB agent), and flecain-
ide (a Class IC agent).5 Based on this case report, psychosis 
appears to be a dose-related side effect of mexiletine therapy, 
with a Naranjo probability score6 of 7, because the patient 
did not have any neuropsychiatric symptoms on a dose of 
150 mg twice a day. Lidocaine is the most extensively studied 
Class I antiarrhythmic medication and has common neuro-
psychiatric side effects which appear to be dose-related. We 
believe psychosis and other neurological side effects may 
represent an effect of sodium channel blockade, because this 
seems to be a class effect of the Class I antiarrhythmic agents.   
We suggest caution during uptitration of the mexiletine dose 
because it may potentially lead to psychosis which can, in 
some circumstances, be life-threatening.
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